
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES68
The evidence appraised suggested that acarbose (used as monotherapy or in combination)
failed to demonstrate better glycaemic control when compared with other oral agents.
Treatment with acarbose did not demonstrate superiority over other oral agents when lipid
profile and body weight were evaluated.

[@Gray_2000]

[@Unkown_date]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

[@Rosenthal_2002]

